2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T63a,Historically, systemic therapy for hormone-sensitive prostate cancer (HSPC) was predicated on androgen-deprivation therapy (ADT) alone. However, in the past decade, substantial improvements have been made by intensifying treatment based on a better understanding of the broad underlying biology of these cancers. The addition of androgen receptor pathway inhibitors (ARPIs), docetaxel and/or radiotherapy to ADT is of proven benefit in certain patient subgroups, whereas AKT inhibitors, radioligand therapies and poly ADP-ribose polymerase (PARP) inhibitors are being evaluated in patients with metastatic HSPC. The clinical states of HSPC are determined by a history of localized prostate cancer versus presentation with de novo metastatic disease, as well as the extent of disease on conventional computed tomography imaging and whole-body bone scintigraphy. However, modern nuclear imaging modalities such as prostate-specific membrane antigen PET can visualize metastases below the limit of detection of computed tomography and whole-body bone scintigraphy; this earlier and more precise detection of metastases has identified new subgroups of patients for which certain treatment approaches, such as adding docetaxel to ADT plus an ARPI, might or might not apply. In this Review, we discuss the personalized management of both non-metastatic and metastatic HSPC, including how to select patients for docetaxel, choice of ARPI and use of radiotherapy to primary and metastatic disease sites. We also discuss emerging novel therapies and important principles of toxicity mitigation for HSPC.31:T628,L.M.B. is a member of the ANZUP Scientific Advisory Committee (unpaid). L.E. reports research grant support (to institution) from Clarity Pharma and Novartis and consulting fees for lectures or advisory boards from Advancell, Astellas, AstraZeneca, Clarity Pharma, Janssen, Novartis and Telix in the past 5 years. C.J.S. declares roles as principal investigator of the CHAARTED trial, study co-chair of the ENZAMET trial and is a member of the ANZUP Scientific Advisory Committee (unpaid); research funding (to institution) from Astellas, Bayer, Janssen, Pfizer and Sanofi; compensated advisory roles for Astellas, Bayer, Genentech/Roche, Hengrui, Janssen, Lilly, Novartis, Pfizer, PointBiopharma and Sanofi; and stock ownership in Leuchemix. C.J.S also holds patents for parthenolide as an anticancer agent, co-authored with H. Nakshatri (WO0145699A1, owned by Indiana University); for use of the drug combination of abiraterone and cabozantinib to treat prostate cancer, co-authors with P. Kantoff (WO 2014/165770 A1 owned by Exelixis); for compositions and methods for screening and diagnosis of prostate cancer with KDM5D biomarker, co-authored with P. Kantoff, G.-S. Mary Lee and K. Komura (WO2017/117486 A1, owned by Dana-Farber Cancer Institute); for compositions and methods for screening and identifying clinically aggressive prostate cancer with SNPs and ZFP36, co-authored with C. Huttenhower, T. Gerke, L. Mucci, G.-S. Mary Lee and D. Bornigen (WO2017127696A, owned by Harvard University and Dana-Farber Cancer Institute). M.A.C. declares no competing interests.32:Te97, PURPOSE Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)–targeting radioligand therapy to SBRT would improve outcomes. METHODS The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177 Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959 ). RESULTS From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177 Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177 Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177 Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177 Lu + SBRT group). Prognostic biomarkers for PFS were identified. CONCLUSION Compared with SBRT alone, the addition of 177 Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Radioligand Therapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Radioligand Therapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Radioligand%20Therapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Radioligand Therapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Radioligand%20Therapy\"}]}}"}}]],["$","$L2f",null,{"title":"Radioligand Therapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Radioligand Therapy — concise summaries and practical next steps.","papers":[{"doi":"10.3390/cancers18142331","pmid":null,"title":"Theranostic Potential of 177Lu-TLX591 with Best Standard-of-Care and 68Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial","journal_title":"Cancers","journal_issn":"2072-6694","published_at":"2026-07-20T00:00:00.000Z","url":"https://doi.org/10.3390/cancers18142331","source_score":44,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-25T13:58:01.047Z","updated_at":"2026-07-25T13:58:01.047Z","tags":[{"paper_doi":"10.3390/cancers18142331","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"brand","value":"Illuccix","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"brand","value":"TLX591","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"condition","value":"Metastatic Castration-Resistant Prostate Cancer","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"generic","value":"177Lu-TLX591","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"generic","value":"gallium Ga-68 gozetotide","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"modality","value":"PET Imaging","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"sample_size","value":"n=30","value_numeric":30},{"paper_doi":"10.3390/cancers18142331","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"study_design","value":"Phase 1 Non-Randomized Trial","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"warning","value":"177Lu-TLX591 is an investigational agent not yet approved; brand name 'TLX591' is a development code, not a commercially approved brand name.","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"warning","value":"Level of evidence assigned as 3 (non-randomized controlled trial/Phase 1); this is debatable given the single-arm design and small sample size — could be argued as level 4.","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"warning","value":"No efficacy endpoints (e.g., PSA response, radiographic progression-free survival) are reported in the abstract; the study was primarily safety and dosimetry focused.","value_numeric":null},{"paper_doi":"10.3390/cancers18142331","tag_type":"warning","value":"The brand tag for gallium Ga-68 gozetotide (Illuccix) is assumed based on common clinical usage; the paper refers to 68Ga-PSMA-11 generically.","value_numeric":null}],"summaries":{"what_studied":"Phase 1 single-arm trial (ProstACT SELECT) evaluated 177Lu-TLX591 — a radio antibody–drug conjugate targeting PSMA — combined with best standard of care in 30 patients with mCRPC who progressed on androgen receptor pathway inhibitors; 68Ga-PSMA-11 PET was used for patient selection and compared with SPECT/CT imaging.","key_result":"Tumor targeting on 177Lu-TLX591 SPECT/CT was qualitatively consistent with 68Ga-PSMA-11 PET; no new safety signals emerged. Highest absorbed dose was to the liver (2.44 ± 0.56 Gy/GBq), while salivary gland (0.07 ± 0.03 Gy/GBq) and kidney (0.64 ± 0.17 Gy/GBq) exposures were low, and tumor activity was retained through 312 hours post-administration.","limitations":"Small sample size (n=30) in a single-arm design limits efficacy conclusions; no randomized comparator arm; qualitative rather than quantitative imaging concordance assessment between PET and SPECT/CT.","practice_takeaway":"68Ga-PSMA-11 PET appears to reliably select mCRPC patients for 177Lu-TLX591 therapy, and the agent's low salivary gland dosimetry may offer a tolerability advantage over other PSMA-targeted radioligand therapies. Larger randomized trials are needed before clinical adoption."}},{"doi":"10.1016/j.eururo.2026.06.009","pmid":"42399196","title":"Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics","journal_title":"European Urology","journal_issn":"0302-2838","published_at":"2026-07-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.eururo.2026.06.009","source_score":11,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-09T13:35:52.417Z","updated_at":"2026-07-09T13:35:52.417Z","tags":[{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"condition","value":"Biochemical Recurrence","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"condition","value":"Metastatic Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"modality","value":"Molecular Imaging","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"sample_size","value":"n=88","value_numeric":88},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"study_design","value":"Expert Consensus Conference / Delphi-Style Survey","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"warning","value":"Full text was inaccessible due to a publisher paywall/CAPTCHA block — all extracted content is based solely on the abstract. Specific panel voting breakdowns, panellist demographics, and individual question results are not available.","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"warning","value":"Sample size tag reflects the number of consensus questions voted on (n=88), not a patient cohort — interpret accordingly.","value_numeric":null},{"paper_doi":"10.1016/j.eururo.2026.06.009","tag_type":"warning","value":"Study design is a consensus conference/expert survey, which may be labeled ambiguously between 'Delphi' and 'consensus conference' formats; treat level of evidence conservatively.","value_numeric":null}],"summaries":{"what_studied":"The APCCC Diagnostics 2025 consensus conference evaluated 88 multiple-choice questions across six clinical topics related to prostate cancer diagnosis, staging, and restaging (including biochemical recurrence, metastatic disease monitoring, and radioligand therapy/imaging), with expert panel voting conducted via web-based survey.","key_result":"Consensus (≥75% agreement) was reached on only 17 of 88 questions (19%), with strong consensus (≥90%) on just 6 (7%). Highest consensus rates were in staging (7/16, 44%) and lowest in monitoring metastatic disease (0/18, 0%).","limitations":"Full text was not accessible — only the abstract was available, so specific voting results, panel composition, and detailed clinical recommendations cannot be assessed. The consensus format reflects expert opinion rather than primary evidence, and the pilot design limits generalizability.","practice_takeaway":"Broad disagreement among experts highlights that most decisions around prostate cancer diagnosis and restaging lack high-level evidence — clinicians should approach these areas with awareness of uncertainty. Priority topics for future research include monitoring metastatic prostate cancer and radioligand therapy imaging guidance."}},{"doi":"10.1016/j.euf.2026.06.014","pmid":"42366147","title":"Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide","journal_title":"European Urology Focus","journal_issn":"2405-4569","published_at":"2026-06-28T00:00:00.000Z","url":"https://doi.org/10.1016/j.euf.2026.06.014","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-06T13:36:15.342Z","updated_at":"2026-07-06T13:36:15.342Z","tags":[{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"brand","value":"Pluvicto","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"condition","value":"Metastatic Castration-Resistant Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"condition","value":"Metastatic Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"condition","value":"Prostate Cancer","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"generic","value":"lutetium Lu 177 vipivotide tetraxetan","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"modality","value":"PSMA-Targeted Therapy","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"study_design","value":"Clinical Practice Guideline / Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"warning","value":"Publication date (2026-06-28) is very recent relative to today's date (2026-07-06); downstream guideline updates may not yet reflect this review.","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"warning","value":"The generic name used ('lutetium Lu 177 vipivotide tetraxetan') reflects the FDA-approved RxNorm form; the paper refers to the compound as '[177Lu]Lu-PSMA-617'.","value_numeric":null},{"paper_doi":"10.1016/j.euf.2026.06.014","tag_type":"warning","value":"This paper is a narrative clinical consultation guide, not a primary trial — no new efficacy or safety data are reported. Level of evidence reflects expert review, not a controlled study.","value_numeric":null}],"summaries":{"what_studied":"This clinical consultation guide summarizes evidence, patient selection strategies, toxicity monitoring, and future directions for PSMA-targeted radioligand therapy ([177Lu]Lu-PSMA-617) in prostate cancer, drawing on landmark trials (VISION, TheraP, PSMAfore) across mCRPC and emerging earlier-line settings.","key_result":"VISION, TheraP, and PSMAfore trials established that [177Lu]Lu-PSMA-617 improves overall survival, progression-free survival, and biochemical response rates in mCRPC; evidence is expanding to taxane-naïve disease, metastatic hormone-sensitive prostate cancer, and neoadjuvant settings.","limitations":"This is a narrative consultation guide, not a primary study — no new patient-level data are presented. Emerging imaging biomarkers for patient selection are described as investigational only. Evidence for earlier-line use (mHSPC, neoadjuvant) remains preliminary.","practice_takeaway":"Patient selection for PSMA-RLT should rely on PSMA PET imaging, disease burden assessment, and multidisciplinary team review. Clinicians should monitor for known toxicities and watch for evolving evidence supporting earlier use beyond heavily pretreated mCRPC."}},{"doi":"10.1097/ju.0000000000005131","pmid":"42171515","title":"First-Line Systemic Treatments of Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-Analysis","journal_title":"Journal of Urology","journal_issn":"0022-5347","published_at":"2026-05-22T00:00:00.000Z","url":"https://doi.org/10.1097/ju.0000000000005131","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-14T13:24:59.421Z","updated_at":"2026-08-14T13:24:59.421Z","tags":[{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Erleada","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Nubeqa","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Pluvicto","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Xtandi","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Zytiga","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"condition","value":"Metastatic Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"abiraterone","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"apalutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"capivasertib","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"darolutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"enzalutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"lutetium-177 PSMA-617","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"niraparib","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"AKT Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Androgen Deprivation Therapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Androgen Receptor Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"PARP Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"sample_size","value":"n=18689","value_numeric":18689},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"study_design","value":"Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"Biomarker-driven trials (AMPLITUDE, CAPItello-281, PSMAddition) were excluded from the NMA due to selected populations and evaluated qualitatively only; OS results are immature for all three.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"PARPi+ARPI+ADT OS data were not available for inclusion in the NMA; OS benefit for this triplet remains unknown.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"Several included trials had open-label designs, introducing risk of bias in investigator-assessed progression endpoints.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the high-certainty subgroup finding for docetaxel triplet in high-volume disease and the emerging biomarker-driven data; the all-comer analysis does not confirm a practice change for unselected patients.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"The NMA grouped all ARPIs (abiraterone, apalutamide, darolutamide, enzalutamide, orteronel, rezvilutamide) as a single class to preserve network connectivity; class-level effects may mask agent-specific differences.","value_numeric":null}],"summaries":{"what_studied":"This updated systematic review and network meta-analysis (NMA) compared the efficacy and safety of first-line systemic combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC) across 23 RCTs (n=18,689), searched through March 2026. Outcomes included progression-free survival (PFS), overall survival (OS), and severe adverse events (AEs), with a separate systematic review of biomarker-driven trials (AMPLITUDE, CAPItello-281, PSMAddition).","key_result":"No triplet regimen showed a statistically significant OS benefit over ARPI+ADT in all-comers. However, **docetaxel+ARPI+ADT** significantly improved OS in high-volume disease (HR 0.76, 95% CI 0.61–0.95; high certainty). For PFS, docetaxel+ARPI+ADT (HR 0.66, 95% CI 0.43–1.01; moderate certainty) and PARPi+ARPI+ADT (HR 0.55, 95% CI 0.23–1.34; low certainty) showed clinically relevant but non-significant trends vs. ARPI+ADT. In biomarker-selected populations: niraparib+abiraterone improved rPFS in HRR-mutated mHSPC (HR 0.63); capivasertib+abiraterone improved rPFS in PTEN-deficient mHSPC (HR 0.81); Lu-177-PSMA+ARPI+ADT improved rPFS in PSMA-positive mHSPC (HR 0.72); OS data remain immature for all three.","limitations":"- Direct head-to-head comparisons between key triplet regimens were unavailable, requiring reliance on indirect NMA contrasts with interstudy heterogeneity.\n- Combining radiographic and clinical PFS endpoints introduced heterogeneity; earlier trials used conventional imaging vs. more sensitive modalities in recent trials, risking stage migration bias.\n- PARPi-, PSMA-, and AKT-based evidence comes from single trials with immature OS data and small phase II samples, yielding low or very low certainty.","practice_takeaway":"For patients with **high-volume mHSPC**, docetaxel+ARPI+ADT offers a proven OS benefit (HR 0.76; high certainty) and should be preferred. For patients with specific biomarkers (HRR mutation, PTEN loss, or PSMA-positive disease), targeted intensification with PARPi, AKT inhibitor, or radioligand therapy respectively shows rPFS benefit—but OS data are still maturing, so treatment decisions must weigh distinct toxicity profiles against uncertain long-term gains."}},{"doi":"10.1038/s41571-025-01100-3","pmid":"41310272","title":"Personalized intensification of treatment for hormone-sensitive prostate cancer","journal_title":"Nature Reviews Clinical Oncology","journal_issn":"1759-4774","published_at":"2025-11-28T00:00:00.000Z","url":"https://doi.org/10.1038/s41571-025-01100-3","source_score":86,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-02","doi":"10.1038/s41571-025-01100-3","days":"7","issn":"1759-4774","rank":"3","field":"Clinical Medicine","score":"86","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1038/s41571-025-01100-3","title":"Personalized intensification of treatment for hormone-sensitive prostate cancer.","journal":"Nature reviews. Clinical oncology","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41310272","conclusions":"","publication_date":"2025-11-28T00:00:00"},"crossref":{"DOI":"10.1038/s41571-025-01100-3","URL":"https://doi.org/10.1038/s41571-025-01100-3","ISSN":["1759-4774","1759-4782"],"link":[{"URL":"https://www.nature.com/articles/s41571-025-01100-3.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41571-025-01100-3","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41571-025-01100-3.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Personalized intensification of treatment for hormone-sensitive prostate cancer"],"author":[{"given":"Michael A.","family":"Cilento","sequence":"first","affiliation":[]},{"given":"Lisa M.","family":"Butler","sequence":"additional","affiliation":[]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11,27]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2025-11-27T11:39:32Z","timestamp":1764243572000,"date-parts":[[2025,11,27]]},"indexed":{"date-time":"2025-11-27T13:05:20Z","timestamp":1764248720499,"date-parts":[[2025,11,27]]},"license":[{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000,"date-parts":[[2025,11,27]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000,"date-parts":[[2025,11,27]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s41571-025-01100-3"}},"subtitle":[],"assertion":[{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":1,"value":"29 October 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":2,"value":"27 November 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"$31"}],"deposited":{"date-time":"2025-11-27T13:02:54Z","timestamp":1764248574000,"date-parts":[[2025,11,27]]},"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"published":{"date-parts":[[2025,11,27]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1002/ijc.35278","key":"1100_CR1","year":"2024","issue":null,"author":"AM Filho","volume":"156","first-page":"1336","unstructured":"Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer 156, 1336–1346 (2024).","article-title":null,"journal-title":"Int. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)00651-2","key":"1100_CR2","year":"2024","issue":null,"author":"ND James","volume":"403","first-page":"1683","unstructured":"James, N. D. et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683–1722 (2024).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1093/jnci/djaa068","key":"1100_CR3","year":"2021","issue":null,"author":"A Jemal","volume":"113","first-page":"64","unstructured":"Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US preventive services task force recommendations against screening. J. Natl Cancer Inst. 113, 64–71 (2021).","article-title":null,"journal-title":"J. Natl Cancer Inst.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2214122","key":"1100_CR4","year":"2023","issue":null,"author":"FC Hamdy","volume":"388","first-page":"1547","unstructured":"Hamdy, F. C. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 388, 1547–1558 (2023).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)02437-5","key":"1100_CR5","year":"2022","issue":null,"author":"G Attard","volume":"399","first-page":"447","unstructured":"Attard, G. et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399, 447–460 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.31384","key":"1100_CR6","year":"2018","issue":null,"author":"JT Helgstrand","volume":"124","first-page":"2931","unstructured":"Helgstrand, J. T. et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-a population-based analysis of 2 national cohorts. Cancer 124, 2931–2938 (2018).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.03.027","key":"1100_CR7","year":"2024","issue":null,"author":"P Cornford","volume":"86","first-page":"148","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148–163 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.1.2025. National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 31 January 2025).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.urology.2007.08.055","key":"1100_CR9","year":"2007","issue":null,"author":"DJ Hernandez","volume":"70","first-page":"931","unstructured":"Hernandez, D. J., Nielsen, M. E., Han, M. & Partin, A. W. Contemporary evaluation of the D’amico risk classification of prostate cancer. Urology 70, 931–935 (2007).","article-title":null,"journal-title":"Urology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2022.12.035","key":"1100_CR10","year":"2023","issue":null,"author":"PL Nguyen","volume":"116","first-page":"521","unstructured":"Nguyen, P. L. et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the nrg oncology/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 116, 521–529 (2023).","article-title":null,"journal-title":"Int. J. Radiat. Oncol. Biol. Phys.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2017.09.013","key":"1100_CR11","year":"2018","issue":null,"author":"SK Van Den Eeden","volume":"73","first-page":"129","unstructured":"Van Den Eeden, S. K. et al. A Biopsy-based 17-gene Genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur. Urol. 73, 129–138 (2018).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(10)70295-3","key":"1100_CR12","year":"2011","issue":null,"author":"J Cuzick","volume":"12","first-page":"245","unstructured":"Cuzick, J. et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245–255 (2011).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.01.004","key":"1100_CR13","year":"2024","issue":null,"author":"AE Ross","volume":"7","first-page":"1024","unstructured":"Ross, A. E. et al. External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG/RTOG 9902 phase 3 trial. Eur. Urol. Oncol. 7, 1024–1033 (2024).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR14","year":"1941","issue":null,"author":"C Huggins","volume":"1","first-page":"293","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).","article-title":null,"journal-title":"Cancer Res.","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2303974","key":"1100_CR15","year":"2023","issue":null,"author":"SJ Freedland","volume":"389","first-page":"1453","unstructured":"Freedland, S. J. et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389, 1453–1465 (2023).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.25993","key":"1100_CR16","year":"2011","issue":null,"author":"SE Cotter","volume":"117","first-page":"3925","unstructured":"Cotter, S. E. et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117, 3925–3932 (2011).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)31553-1","key":"1100_CR17","year":"2020","issue":null,"author":"CC Parker","volume":"396","first-page":"1413","unstructured":"Parker, C. C. et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396, 1413–1421 (2020).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30456-3","key":"1100_CR18","year":"2020","issue":null,"author":"A Kneebone","volume":"21","first-page":"1331","unstructured":"Kneebone, A. et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 21, 1331–1340 (2020).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30454-X","key":"1100_CR19","year":"2020","issue":null,"author":"P Sargos","volume":"21","first-page":"1341","unstructured":"Sargos, P. et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 21, 1341–1352 (2020).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(19)30486-3","key":"1100_CR20","year":"2019","issue":null,"author":"C Carrie","volume":"20","first-page":"1740","unstructured":"Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)01790-6","key":"1100_CR21","year":"2022","issue":null,"author":"A Pollack","volume":"399","first-page":"1886","unstructured":"Pollack, A. et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399, 1886–1901 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.07.026","key":"1100_CR22","year":"2024","issue":null,"author":"CC Parker","volume":"86","first-page":"422","unstructured":"Parker, C. C. et al. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). Eur. Urol. 86, 422–430 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1607529","key":"1100_CR23","year":"2017","issue":null,"author":"WU Shipley","volume":"376","first-page":"417","unstructured":"Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-025-00937-0","key":"1100_CR24","year":"2025","issue":null,"author":"P Ravi","volume":null,"first-page":null,"unstructured":"Ravi, P. et al. Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-025-00937-0 (2025).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2020.11.010","key":"1100_CR25","year":"2021","issue":null,"author":"LF Valle","volume":"80","first-page":"280","unstructured":"Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280–292 (2021).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.04.010","key":"1100_CR26","year":"2024","issue":null,"author":"D Tilki","volume":"86","first-page":"164","unstructured":"Tilki, D. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 86, 164–182 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/JU.0000000000001375","key":"1100_CR27","year":"2021","issue":null,"author":"WT Lowrance","volume":"205","first-page":"14","unstructured":"Lowrance, W. T. et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J. Urol. 205, 14–21 (2021).","article-title":null,"journal-title":"J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.03256","key":"1100_CR28","year":"2021","issue":null,"author":"KS Virgo","volume":"39","first-page":"1274","unstructured":"Virgo, K. S. et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J. Clin. Oncol. 39, 1274–1305 (2021).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/PAS.0000000000000530","key":"1100_CR29","year":"2016","issue":null,"author":"JI Epstein","volume":"40","first-page":"244","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 (2016).","article-title":null,"journal-title":"Am. J. Surg. Pathol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2019.03.016","key":"1100_CR30","year":"2019","issue":null,"author":"D Tilki","volume":"75","first-page":"896","unstructured":"Tilki, D., Preisser, F., Graefen, M., Huland, H. & Pompe, R. S. External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a european cohort. Eur. Urol. 75, 896–900 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(16)00107-8","key":"1100_CR31","year":"2016","issue":null,"author":"GM Duchesne","volume":"17","first-page":"727","unstructured":"Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(17)30426-6","key":"1100_CR32","year":"2017","issue":null,"author":"GM Duchesne","volume":"18","first-page":"1192","unstructured":"Duchesne, G. M. et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 18, 1192–1201 (2017).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.01157","key":"1100_CR33","year":"2024","issue":null,"author":"R Aggarwal","volume":"42","first-page":"1114","unstructured":"Aggarwal, R. et al. PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J. Clin. Oncol. 42, 1114–1123 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1201546","key":"1100_CR34","year":"2012","issue":null,"author":"JM Crook","volume":"367","first-page":"895","unstructured":"Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/EVIDoa2300251","key":"1100_CR35","year":"2023","issue":null,"author":"SJ Freedland","volume":"2","first-page":"EVIDoa2300251","unstructured":"Freedland, S. J. et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid. 2, EVIDoa2300251 (2023).","article-title":null,"journal-title":"NEJM Evid.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.73.9987","key":"1100_CR36","year":"2017","issue":null,"author":"W Xie","volume":"35","first-page":"3097","unstructured":"Xie, W. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol. 35, 3097–3104 (2017).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2510310","key":"1100_CR37","year":"2025","issue":null,"author":"ND Shore","volume":null,"first-page":null,"unstructured":"Shore, N. D. et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2510310 (2025).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30730-0","key":"1100_CR38","year":"2021","issue":null,"author":"LA Gharzai","volume":"22","first-page":"402","unstructured":"Gharzai, L. A. et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 22, 402–410 (2021).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO-25-01693","key":"1100_CR39","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Einstein, D. J. et al. National Cancer Institute’s Working Group on biochemically recurrent prostate cancer: clinical trial design considerations. J. Clin. Oncol. https://doi.org/10.1200/JCO-25-01693.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.52971","key":"1100_CR40","year":"2025","issue":null,"author":"A Holzgreve","volume":"8","first-page":null,"unstructured":"Holzgreve, A. et al. PSMA-PET/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw. Open. 8, e2452971 (2025).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)30314-7","key":"1100_CR41","year":"2020","issue":null,"author":"MS Hofman","volume":"395","first-page":"1208","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1503747","key":"1100_CR42","year":"2015","issue":null,"author":"CJ Sweeney","volume":"373","first-page":"737","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(15)01037-5","key":"1100_CR43","year":"2016","issue":null,"author":"ND James","volume":"387","first-page":"1163","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2119115","key":"1100_CR44","year":"2022","issue":null,"author":"MR Smith","volume":"386","first-page":"1132","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386, 1132–1142 (2022).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(22)00367-1","key":"1100_CR45","year":"2022","issue":null,"author":"K Fizazi","volume":"399","first-page":"1695","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 399, 1695–1707 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1704174","key":"1100_CR46","year":"2017","issue":null,"author":"K Fizazi","volume":"377","first-page":"352","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/ijc.34018","key":"1100_CR47","year":"2022","issue":null,"author":"ND James","volume":"151","first-page":"422","unstructured":"James, N. D. et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer 151, 422–434 (2022).","article-title":null,"journal-title":"Int. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1903307","key":"1100_CR48","year":"2019","issue":null,"author":"KN Chi","volume":"381","first-page":"13","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1903835","key":"1100_CR49","year":"2019","issue":null,"author":"ID Davis","volume":"381","first-page":"121","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO-24-01798","key":"1100_CR50","year":"2024","issue":null,"author":"F Saad","volume":"42","first-page":"4271","unstructured":"Saad, F. et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J. Clin. Oncol. 42, 4271–4281 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)32486-3","key":"1100_CR51","year":"2018","issue":null,"author":"CC Parker","volume":"392","first-page":"2353","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.75.3657","key":"1100_CR52","year":"2018","issue":null,"author":"CE Kyriakopoulos","volume":"36","first-page":"1080","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080–1087 (2018).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdz396","key":"1100_CR53","year":"2019","issue":null,"author":"NW Clarke","volume":"30","first-page":"1992","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992–2003 (2019).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00230-9","key":"1100_CR54","year":"2023","issue":null,"author":"CL Vale","volume":"24","first-page":"783","unstructured":"Vale, C. L. et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 24, 783–797 (2023).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(12)70560-0","key":"1100_CR55","year":"2013","issue":null,"author":"G Gravis","volume":"14","first-page":"149","unstructured":"Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1702900","key":"1100_CR56","year":"2017","issue":null,"author":"ND James","volume":"377","first-page":"338","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/jcph.564","key":"1100_CR57","year":"2015","issue":null,"author":"KN Chi","volume":"55","first-page":"1406","unstructured":"Chi, K. N. et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J. Clin. Pharmacol. 55, 1406–1414 (2015).","article-title":null,"journal-title":"J. Clin. Pharmacol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2007.15.9749","key":"1100_CR58","year":"2008","issue":null,"author":"G Attard","volume":"26","first-page":"4563","unstructured":"Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563–4571 (2008).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(19)30082-8","key":"1100_CR59","year":"2019","issue":null,"author":"K Fizazi","volume":"20","first-page":"686","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686–700 (2019).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.5_suppl.20","key":"1100_CR60","year":"2025","issue":null,"author":"DJ Fisher","volume":"43","first-page":"20","unstructured":"Fisher, D. J. et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). J. Clin. Oncol. 43, 20–20 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.03488","key":"1100_CR61","year":"2021","issue":null,"author":"KN Chi","volume":"39","first-page":"2294","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39, 2294–2303 (2021).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.113290","key":"1100_CR62","year":"2023","issue":null,"author":"AS Merseburger","volume":"193","first-page":"113290","unstructured":"Merseburger, A. S. et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study. Eur. J. Cancer 193, 113290 (2023).","article-title":null,"journal-title":"Eur. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1530/ETJ-24-0158","key":"1100_CR63","year":"2024","issue":null,"author":"K David","volume":"13","first-page":null,"unstructured":"David, K. et al. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. Eur. Thyroid J. 13, e240158 (2024).","article-title":null,"journal-title":"Eur. Thyroid J.","doi-asserted-by":"publisher"},{"DOI":"10.1210/jendso/bvae105","key":"1100_CR64","year":"2024","issue":null,"author":"C Moffatt","volume":"8","first-page":"bvae105","unstructured":"Moffatt, C. et al. The effect of apalutamide on thyroid function in prostate cancer patients. J. Endocr. Soc. 8, bvae105 (2024).","article-title":null,"journal-title":"J. Endocr. Soc.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00063-3","key":"1100_CR65","year":"2023","issue":null,"author":"CJ Sweeney","volume":"24","first-page":"323","unstructured":"Sweeney, C. J. et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 323–334 (2023).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.5090","key":"1100_CR66","year":"2025","issue":null,"author":"AY Zhang","volume":"43","first-page":"5090","unstructured":"Zhang, A. Y. et al. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). J. Clin. Oncol. 43, 5090–5090 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.21.00941","key":"1100_CR67","year":"2022","issue":null,"author":"MR Stockler","volume":"40","first-page":"837","unstructured":"Stockler, M. R. et al. Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP. J. Clin. Oncol. 40, 837–846 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1111/bcp.13425","key":"1100_CR68","year":"2018","issue":null,"author":"GE Benoist","volume":"84","first-page":"122","unstructured":"Benoist, G. E. et al. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br. J. Clin. Pharmacol. 84, 122–129 (2018).","article-title":null,"journal-title":"Br. J. Clin. Pharmacol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.00799","key":"1100_CR69","year":"2019","issue":null,"author":"AJ Armstrong","volume":"37","first-page":"2974","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974–2986 (2019).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.5005","key":"1100_CR70","year":"2025","issue":null,"author":"AJ Armstrong","volume":"43","first-page":"5005","unstructured":"Armstrong, A. J. et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J. Clin. Oncol. 43, 5005–5005 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13318-019-00577-5","key":"1100_CR71","year":"2019","issue":null,"author":"C Zurth","volume":"44","first-page":"747","unstructured":"Zurth, C. et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur. J. Drug. Metab. Pharmacokinet. 44, 747–759 (2019).","article-title":null,"journal-title":"Eur. J. Drug. Metab. Pharmacokinet.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2020.7857","key":"1100_CR72","year":"2021","issue":null,"author":"A Ali","volume":"7","first-page":"555","unstructured":"Ali, A. et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 7, 555–563 (2021).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2019.02.003","key":"1100_CR73","year":"2019","issue":null,"author":"S Burdett","volume":"76","first-page":"115","unstructured":"Burdett, S. et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur. Urol. 76, 115–124 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euf.2024.06.009","key":"1100_CR74","year":"2025","issue":null,"author":"JE Bibault","volume":"11","first-page":"76","unstructured":"Bibault, J. E., Méjean, A., Hyafil, F., Thibault, C. & Oudard, S. Radiation therapy for locally advanced prostate cancer: how do we treat patients with cN1 disease? Eur. Urol. Focus. 11, 76–78 (2025).","article-title":null,"journal-title":"Eur. Urol. Focus.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)01865-8","key":"1100_CR75","year":"2024","issue":null,"author":"A Bossi","volume":"404","first-page":"2065","unstructured":"Bossi, A. et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 404, 2065–2076 (2024).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.75.4853","key":"1100_CR76","year":"2018","issue":null,"author":"P Ost","volume":"36","first-page":"446","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2020.0147","key":"1100_CR77","year":"2020","issue":null,"author":"R Phillips","volume":"6","first-page":"650","unstructured":"Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650–659 (2020).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00644","key":"1100_CR78","year":"2022","issue":null,"author":"MP Deek","volume":"40","first-page":"3377","unstructured":"Deek, M. P. et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J. Clin. Oncol. 40, 3377–3382 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2023.0161","key":"1100_CR79","year":"2023","issue":null,"author":"C Tang","volume":"9","first-page":"825","unstructured":"Tang, C. et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the extend phase 2 randomized clinical trial. JAMA Oncol. 9, 825–834 (2023).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.03.010","key":"1100_CR80","year":"2024","issue":null,"author":"MP Deek","volume":"7","first-page":"1403","unstructured":"Deek, M. P. et al. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer. Eur. Urol. Oncol. 7, 1403–1410 (2024).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.00041","key":"1100_CR81","year":"2023","issue":null,"author":"M Hussain","volume":"41","first-page":"3595","unstructured":"Hussain, M. et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J. Clin. Oncol. 41, 3595–3607 (2023).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.30.7025","key":"1100_CR82","year":"2010","issue":null,"author":"RM Franke","volume":"28","first-page":"4562","unstructured":"Franke, R. M., Carducci, M. A., Rudek, M. A., Baker, S. D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562–4567 (2010).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2014.07.020","key":"1100_CR83","year":"2015","issue":null,"author":"G Gandaglia","volume":"68","first-page":"325","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325–334 (2015).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.urolonc.2025.02.007","key":"1100_CR84","year":"2025","issue":null,"author":"F Urabe","volume":"43","first-page":"336.e1","unstructured":"Urabe, F. et al. Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study. Urol. Oncol. 43, 336.e1–336.e11 (2025).","article-title":null,"journal-title":"Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-020-0255-x","key":"1100_CR85","year":"2020","issue":null,"author":"R Iacovelli","volume":"23","first-page":"654","unstructured":"Iacovelli, R. et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 23, 654–660 (2020).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.04.010","key":"1100_CR86","year":"2025","issue":null,"author":"D Sentana-Lledo","volume":"8","first-page":"29","unstructured":"Sentana-Lledo, D. et al. Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED). Eur. Urol. Oncol. 8, 29–37 (2025).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2019.07.009","key":"1100_CR87","year":"2019","issue":null,"author":"K Mori","volume":"17","first-page":"409","unstructured":"Mori, K. et al. Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis. Clin. Genitourin. Cancer 17, 409–418 (2019).","article-title":null,"journal-title":"Clin. Genitourin. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1159/000020289","key":"1100_CR88","year":"2000","issue":null,"author":"A Sella","volume":"38","first-page":"250","unstructured":"Sella, A., Konichezky, M., Flex, D., Sulkes, A. & Baniel, J. Low PSA metastatic androgen- independent prostate cancer. Eur. Urol. 38, 250–254 (2000).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00432-021-03642-2","key":"1100_CR89","year":"2022","issue":null,"author":"B Lim","volume":"148","first-page":"727","unstructured":"Lim, B. et al. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer. J. Cancer Res. Clin. Oncol. 148, 727–734 (2022).","article-title":null,"journal-title":"J. Cancer Res. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2018.11.045","key":"1100_CR90","year":"2019","issue":null,"author":"AA Hamid","volume":"76","first-page":"89","unstructured":"Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76, 89–97 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-021-00430-4","key":"1100_CR91","year":"2022","issue":null,"author":"MG Velez","volume":"25","first-page":"479","unstructured":"Velez, M. G. et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 25, 479–483 (2022).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-025-00936-1","key":"1100_CR92","year":"2025","issue":null,"author":"G Gebrael","volume":null,"first-page":null,"unstructured":"Gebrael, G. et al. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-025-00936-1 (2025).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2021.09.030","key":"1100_CR93","year":"2022","issue":null,"author":"RP Graf","volume":"81","first-page":"37","unstructured":"Graf, R. P. et al. Predictive genomic biomarkers of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer. Eur. Urol. 81, 37–47 (2022).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.12.015","key":"1100_CR94","year":"2025","issue":null,"author":"JS de Bono","volume":"87","first-page":"672","unstructured":"de Bono, J. S. et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur. Urol. 87, 672–682 (2025).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.urolonc.2024.05.010","key":"1100_CR95","year":"2024","issue":null,"author":"S Custodio-Cabello","volume":"42","first-page":"331.e13","unstructured":"Custodio-Cabello, S. et al. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC). Urol. Oncol. 42, 331.e13–331.e24 (2024).","article-title":null,"journal-title":"Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2018.5801","key":"1100_CR96","year":"2019","issue":null,"author":"W Abida","volume":"5","first-page":"471","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478 (2019).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.TPS5129","key":"1100_CR97","year":"2025","issue":null,"author":"M Ong","volume":"43","first-page":"TPS5129","unstructured":"Ong, M. et al. TRIPLE-SWITCH (SWOG/CCTG-PR26): a randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). J. Clin. Oncol. 43, TPS5129–TPS5129 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00440-6","key":"1100_CR98","year":"2024","issue":null,"author":"AA Azad","volume":"25","first-page":"1267","unstructured":"Azad, A. A. et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267–1276 (2024).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2025.09.101","key":"1100_CR99","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Tagawa, S. T. et al. LBA6 — Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition) (ESMO Congress, 2025).","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.annonc.2024.08.1739","key":"1100_CR100","year":"2024","issue":null,"author":"M Padden-Modi","volume":"35","first-page":"S999","unstructured":"Padden-Modi, M. et al. 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S999–S1000 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2023-0526","key":"1100_CR101","year":"2024","issue":null,"author":"N Agarwal","volume":"20","first-page":"493","unstructured":"Agarwal, N. et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 20, 493–505 (2024).","article-title":null,"journal-title":"Future Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.17_suppl.LBA5006","key":"1100_CR102","year":"2025","issue":null,"author":"G Attard","volume":"43","first-page":"LBA5006","unstructured":"Attard, G. et al. Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J. Clin. Oncol. 43, LBA5006–LBA5006 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-025-03961-8","key":"1100_CR103","year":"2025","issue":null,"author":"G Attard","volume":null,"first-page":null,"unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. https://doi.org/10.1038/s41591-025-03961-8 (2025).","article-title":null,"journal-title":"Nat. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2024.42.16_suppl.TPS5123","key":"1100_CR104","year":"2024","issue":null,"author":"KN Chi","volume":"42","first-page":"TPS5123","unstructured":"Chi, K. N. et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J. Clin. Oncol. 42, TPS5123–TPS5123 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2024.08.1737","key":"1100_CR105","year":"2024","issue":null,"author":"S Howlett","volume":"35","first-page":"S998","unstructured":"Howlett, S. et al. 1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S998–S999 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2025.10.004","key":"1100_CR106","year":"2025","issue":null,"author":"K Fizazi","volume":null,"first-page":null,"unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2025.10.004 (2025).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00580-8","key":"1100_CR107","year":"2021","issue":null,"author":"C Sweeney","volume":"398","first-page":"131","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131–142 (2021).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1212299","key":"1100_CR108","year":"2013","issue":null,"author":"M Hussain","volume":"368","first-page":"1314","unstructured":"Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.5_suppl.268","key":"1100_CR109","year":"2025","issue":null,"author":"A Sokolova","volume":"43","first-page":"268","unstructured":"Sokolova, A. et al. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. J. Clin. Oncol. 43, 268–268 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/ageing/afp221","key":"1100_CR110","year":"2010","issue":null,"author":"PN Kannegaard","volume":"39","first-page":"203","unstructured":"Kannegaard, P. N., van der Mark, S., Eiken, P. & Abrahamsen, B. Excess mortality in men compared with women following a hip fracture. national analysis of comedications, comorbidity and survival. Age Ageing 39, 203–209 (2010).","article-title":null,"journal-title":"Age Ageing","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41584-024-01094-9","key":"1100_CR111","year":"2024","issue":null,"author":"NR Fuggle","volume":"20","first-page":"241","unstructured":"Fuggle, N. R. et al. Evidence-based guideline for the management of osteoporosis in men. Nat. Rev. Rheumatol. 20, 241–251 (2024).","article-title":null,"journal-title":"Nat. Rev. Rheumatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11657-018-0510-0","key":"1100_CR112","year":"2018","issue":null,"author":"JA Kanis","volume":"13","first-page":null,"unstructured":"Kanis, J. A., Johansson, H., Harvey, N. C. & McCloskey, E. V. A brief history of FRAX. Arch. Osteoporos. 13, 118 (2018).","article-title":null,"journal-title":"Arch. Osteoporos.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa0809003","key":"1100_CR113","year":"2009","issue":null,"author":"MR Smith","volume":"361","first-page":"745","unstructured":"Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1097/JU.0000000000003452","key":"1100_CR114","year":"2023","issue":null,"author":"W Lowrance","volume":"209","first-page":"1082","unstructured":"Lowrance, W. et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J. Urol. 209, 1082–1090 (2023).","article-title":null,"journal-title":"J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2013.51.6500","key":"1100_CR115","year":"2014","issue":null,"author":"MR Smith","volume":"32","first-page":"1143","unstructured":"Smith, M. R. et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. 32, 1143–1150 (2014).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.2467","key":"1100_CR116","year":"2024","issue":null,"author":"W Fukuokaya","volume":"7","first-page":null,"unstructured":"Fukuokaya, W. et al. Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate. JAMA Netw. Open. 7, e242467 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.121.056810","key":"1100_CR117","year":"2021","issue":null,"author":"RD Lopes","volume":"144","first-page":"1295","unstructured":"Lopes, R. D. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144, 1295–1307 (2021).","article-title":null,"journal-title":"Circulation","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00345-020-03433-3","key":"1100_CR118","year":"2021","issue":null,"author":"P Davey","volume":"39","first-page":"307","unstructured":"Davey, P. & Kirby, M. G. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J. Urol. 39, 307–315 (2021).","article-title":null,"journal-title":"World J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2013.49.5523","key":"1100_CR119","year":"2014","issue":null,"author":"JR Gardner","volume":"32","first-page":"335","unstructured":"Gardner, J. R., Livingston, P. M. & Fraser, S. F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J. Clin. Oncol. 32, 335–346 (2014).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2014.07.010","key":"1100_CR120","year":"2015","issue":null,"author":"PL Nguyen","volume":"67","first-page":"825","unstructured":"Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825–836 (2015).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(09)70338-9","key":"1100_CR121","year":"2010","issue":null,"author":"J Irani","volume":"11","first-page":"147","unstructured":"Irani, J., Salomon, L., Oba, R., Bouchard, P. & Mottet, N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 11, 147–154 (2010).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00085-5","key":"1100_CR122","year":"2023","issue":null,"author":"S Lederman","volume":"401","first-page":"1091","unstructured":"Lederman, S. et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 401, 1091–1102 (2023).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2412361","key":"1100_CR123","year":"2025","issue":null,"author":"KL Lin","volume":"392","first-page":"202","unstructured":"Lin, K. L., Shekar, S., Crumbaker, M. & Joshua, A. M. Neurokinin-3 receptor antagonism for refractory hot flashes in men. N. Engl. J. Med. 392, 202–203 (2025).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR124","year":"2024","issue":null,"author":"D Sentana-Lledo","volume":"23","first-page":null,"unstructured":"Sentana-Lledo, D., Saraf, A. & Morgans, A. K. Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy. J. Natl Compr. Canc. Netw. 23, e247047 (2024).","article-title":null,"journal-title":"J. Natl Compr. Canc. Netw.","doi-asserted-by":null},{"DOI":"10.1038/s41391-023-00785-w","key":"1100_CR125","year":"2024","issue":null,"author":"DE Hinojosa-Gonzalez","volume":"27","first-page":"507","unstructured":"Hinojosa-Gonzalez, D. E. et al. Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27, 507–519 (2024).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.31153","key":"1100_CR126","year":"2018","issue":null,"author":"DJ McHugh","volume":"124","first-page":"1326","unstructured":"McHugh, D. J., Root, J. C., Nelson, C. J. & Morris, M. J. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124, 1326–1334 (2018).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2019.04.031","key":"1100_CR127","year":"2019","issue":null,"author":"HJ Boyle","volume":"116","first-page":"116","unstructured":"Boyle, H. J. et al. Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur. J. Cancer 116, 116–136 (2019).","article-title":null,"journal-title":"Eur. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-022-00541-6","key":"1100_CR128","year":"2023","issue":null,"author":"LG Briggs","volume":"26","first-page":"331","unstructured":"Briggs, L. G. et al. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer Prostatic Dis. 26, 331–337 (2023).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1210/jcem.87.2.8299","key":"1100_CR129","year":"2002","issue":null,"author":"MR Smith","volume":"87","first-page":"599","unstructured":"Smith, M. R. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87, 599–603 (2002).","article-title":null,"journal-title":"J. Clin. Endocrinol. Metab.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.48707","key":"1100_CR130","year":"2024","issue":null,"author":"N Agarwal","volume":"7","first-page":null,"unstructured":"Agarwal, N. et al. Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw. Open. 7, e2448707 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.09.017","key":"1100_CR131","year":"2025","issue":null,"author":"S Gillessen","volume":"87","first-page":"157","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer. report from the 2024 advanced prostate cancer consensus conference (APCCC). Eur. Urol. 87, 157–216 (2025).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00193","key":"1100_CR132","year":"2022","issue":null,"author":"AJ Armstrong","volume":"40","first-page":"1616","unstructured":"Armstrong, A. J. et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40, 1616–1622 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euros.2024.06.006","key":"1100_CR133","year":"2024","issue":null,"author":"ME Ahmed","volume":"66","first-page":"38","unstructured":"Ahmed, M. E. et al. Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same? Eur. Urol. Open. Sci. 66, 38–45 (2024).","article-title":null,"journal-title":"Eur. Urol. Open. Sci.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.22971","key":"1100_CR134","year":"2007","issue":null,"author":"PE Spiess","volume":"110","first-page":"1729","unstructured":"Spiess, P. E. et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110, 1729–1737 (2007).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.37871","key":"1100_CR135","year":"2024","issue":null,"author":"A Goldkorn","volume":"7","first-page":null,"unstructured":"Goldkorn, A. et al. Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer. JAMA Netw. Open. 7, e2437871 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1002/pros.24787","key":"1100_CR136","year":"2024","issue":null,"author":"F Matrone","volume":"84","first-page":"1468","unstructured":"Matrone, F. et al. Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy. Prostate 84, 1468–1478 (2024).","article-title":null,"journal-title":"Prostate","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2022.06.016","key":"1100_CR137","year":"2022","issue":null,"author":"AM Lee","volume":"20","first-page":"515","unstructured":"Lee, A. M. et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin. Genitourin. Cancer 20, 515–523 (2022).","article-title":null,"journal-title":"Clin. Genitourin. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.02182","key":"1100_CR138","year":"2024","issue":null,"author":"BL Heiss","volume":"42","first-page":"1851","unstructured":"Heiss, B. L. et al. US food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. J. Clin. Oncol. 42, 1851–1860 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-20-0168","key":"1100_CR139","year":"2020","issue":null,"author":"KH Stopsack","volume":"26","first-page":"3230","unstructured":"Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2024.08.1677","key":"1100_CR140","year":"2024","issue":null,"author":"E Grist","volume":"35","first-page":"S961","unstructured":"Grist, E. et al. 1596O decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials. Ann. Oncol. 35, S961–S962 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00326-7","key":"1100_CR141","year":"2024","issue":null,"author":"MJ Karpinski","volume":"25","first-page":"1188","unstructured":"Karpinski, M. J. et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 25, 1188–1201 (2024).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1100"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Nature Reviews Clinical Oncology"],"reference-count":141,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,27]]},"references-count":141,"short-container-title":["Nat Rev Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1038/s41571-025-01100-3","is_oa":false,"title":"Personalized intensification of treatment for hormone-sensitive prostate cancer","updated":"2025-11-28T03:10:16+00:00","published_date":"2025-11-27","best_oa_location":null}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"condition","value":"Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"AKT Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Androgen Receptor Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"PARP Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Radiotherapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"Design classification inferred as a narrative review; not specified as systematic.","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"Narrative review without quantitative outcomes; the abstract provides no effect sizes or event counts.","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"PSMA PET–defined subgroups are mentioned but not detailed in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Review of how to personalize intensification for hormone‑sensitive prostate cancer, covering selection for ARPIs, docetaxel, and radiotherapy with ADT, the impact of PSMA PET staging, and the status of emerging options (AKT inhibitors, radioligand therapies, PARP inhibitors).","practice_takeaway":"Use disease history and extent on conventional imaging to select patients for ARPIs, docetaxel, and radiotherapy with ADT; consider PSMA PET to refine staging, as it can reveal subgroups where adding docetaxel to ADT plus an ARPI may or may not be appropriate."}},{"doi":"10.1200/jco-25-01553","pmid":"41223345","title":"¹⁷⁷\n Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2025-11-12T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-01553","source_score":127,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-22","doi":"10.1200/jco-25-01553","days":"30","issn":"0732-183X","rank":"10","field":"Clinical Medicine","score":"127","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-01553","title":"","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and ","abstract":"Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy to SBRT would improve outcomes.\nThe LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a \nFrom September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and \nCompared with SBRT alone, the addition of ","keywords":[],"pubmed_id":"41223345","conclusions":"Compared with SBRT alone, the addition of ","publication_date":"2025-11-12T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-01553","URL":"https://doi.org/10.1200/jco-25-01553","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-01553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"3812-3821","type":"journal-article","issue":"36","score":1,"title":["¹⁷⁷\n Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study"],"author":[{"given":"Amar U.","family":"Kishan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"},{"name":"Department of Urology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Luca F.","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"},{"name":"Greater Los Angeles VA Medical Center, Los Angeles, CA"}]},{"given":"Holly","family":"Wilhalme","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Carol","family":"Felix","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Rejah","family":"Nabong","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Jesus E.","family":"Juarez-Casillas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Kevin","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"T. Martin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle, WA"}]},{"given":"Vinicius","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Mariko","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"},{"name":"Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Zachary","family":"Ells","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Magnus","family":"Dahlbom","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Michael","family":"Lauria","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Catherine","family":"Meyer","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of San Francisco, San Francisco, CA"}]},{"given":"Joanne B.","family":"Weidhaas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Donatello","family":"Telesca","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Kristen","family":"McGreevy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"},{"name":"Greater Los Angeles VA Medical Center, Los Angeles, CA"}]},{"given":"Danielle","family":"Karasik","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Sophia","family":"Parmisano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"T. Vincent","family":"Basehart","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Wayne","family":"Brisbane","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Leonard","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Greater Los Angeles VA Medical Center, Los Angeles, CA"},{"name":"Department of Medicine, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Los Angeles, Los Angeles, CA"},{"name":"Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Martin","family":"Allen-Auerbach","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[{"name":"Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA"}]}],"issued":{"date-parts":[[2025,12,20]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":"43","created":{"date-time":"2025-11-12T21:00:09Z","timestamp":1762981209000,"date-parts":[[2025,11,12]]},"indexed":{"date-time":"2025-12-17T23:03:13Z","timestamp":1766012593552,"date-parts":[[2025,12,17]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-01553"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-30"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-07-30"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-17"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-11-12"}],"deposited":{"date-time":"2025-12-17T22:59:22Z","timestamp":1766012362000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2025,12,20]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1200/JCO.2017.75.4853","key":"e_1_3_11_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2020.0147","key":"e_1_3_11_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00644","key":"e_1_3_11_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2023.0161","key":"e_1_3_11_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2020.08.030","key":"e_1_3_11_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00730-7","key":"e_1_3_11_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(25)00016-6","key":"e_1_3_11_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2014.07.010","key":"e_1_3_11_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1053/j.semnuclmed.2019.02.008","key":"e_1_3_11_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2025.05.006","key":"e_1_3_11_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2018.08.066","key":"e_1_3_11_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_13_2","year":"2025","issue":null,"author":"Wong CH-M","volume":"35","first-page":"46","unstructured":"Wong CH-M, Nicoletti R, Mazzone E, et al: Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: Current status and future prospects. Curr Opin Urol 35:46-52, 2025","article-title":"Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: Current status and future prospects","journal-title":"Curr Opin Urol","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2107322","key":"e_1_3_11_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)01653-2","key":"e_1_3_11_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00529-6","key":"e_1_3_11_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(25)00009-9","key":"e_1_3_11_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2967/jnumed.121.262713","key":"e_1_3_11_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2967/jnumed.124.267452","key":"e_1_3_11_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bju.15988","key":"e_1_3_11_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/2159-8290.CD-17-0256","key":"e_1_3_11_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Reference Deleted","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Reference Deleted","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.eururo.2022.05.025","key":"e_1_3_11_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO-25-00131","key":"e_1_3_11_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00326-7","key":"e_1_3_11_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2025.04.017","key":"e_1_3_11_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Reference Deleted","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_29_2","year":"2024","issue":null,"author":"Kishan AU","volume":"123","first-page":"266772","unstructured":"Kishan AU, Siva S, Hofman MS, et al: The potential contribution of radiopharmaceutical therapies in managing oligometastatic disease. J Nucl Med 123:266772, 2024","article-title":"The potential contribution of radiopharmaceutical therapies in managing oligometastatic disease","journal-title":"J Nucl Med","doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025,12,20]]}},"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-01553"],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"published-print":{"date-parts":[[2025,12,20]]},"reference-count":28,"published-online":null,"references-count":28,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct05496959"}],"short-container-title":["J Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1200/jco-25-01553","is_oa":true,"title":"¹⁷⁷\n Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study","updated":"2025-12-21T03:41:08+00:00","published_date":"2025-11-12","best_oa_location":{"url":"https://doi.org/10.1200/jco-25-01553","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1200/jco-25-01553"}}},"created_at":"2026-01-16T11:56:46.634Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1200/jco-25-01553","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"condition","value":"Oligorecurrent Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"modality","value":"Stereotactic Body Radiotherapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"sample_size","value":"n=92","value_numeric":92},{"paper_doi":"10.1200/jco-25-01553","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"warning","value":"Abstract text is truncated; outcomes, effect sizes, and adverse events are not available.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01553","tag_type":"warning","value":"Randomization details by arm are incomplete (only SBRT n=47 shown).","value_numeric":null}],"summaries":{"what_studied":"A single-center, open-label, randomized, controlled phase II trial at UCLA tested whether adding neoadjuvant PSMA-targeting radioligand therapy to SBRT improves outcomes for oligorecurrent hormone-sensitive prostate cancer with 1–5 lesions on PSMA PET/CT; 92 patients were randomized between 2022-09-02 and 2023-11-09.","limitations":"Single-center and open-label design."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Radioligand Therapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Radioligand Therapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Radioligand Therapy"}}}]]

Papers